Rituximab and Intravenous Immunoglobulin ( IVIG ) for Refractory Eosinophilic Fasciitis: A Case Report

Clinical Case Reports 2026 Open access

Read full text
Authors: M Sahebari, Motahhareh Karimoddini, Naser Tayyebi Meibodi, Sajad Ataei Azimi, Shadan Tafreshian
DOI: 10.1002/ccr3.71766
Cited by: 1
References: 16

Abstract

Eosinophilic fasciitis (EF) is a rare condition with an unknown cause. This case study showed that a 40-year-old man with EF did not respond to standard treatments but improved after receiving rituximab and intravenous immunoglobulin (IVIG). Further studies are needed to confirm rituximab's effectiveness and long-term safety for EF.

Fields of Study & Subjects

Eosinophilic Disorders and Syndromes Autoimmune and Inflammatory Disorders Soft tissue tumor case studies

Publication details

Journal / source
Clinical Case Reports
Publisher
Wiley
Volume
14
Issue
1
Pages
e71766–e71766
Publication date
1 January 2026
Language
EN